Biosimilar Litigation: Celltrion, Pfizer Claim Victory On Janssen’s Remaining Infringement Claim

Ensnarement defense bars Remicade maker from prevailing on claim that Inflectra partners infringed cell culture media patent, US federal judge rules.

PS1807_Runner-Hurdles_668533522__1200.jpg
Inflectra has cleared the last patent hurdle that posed a potential risk to US marketing.

More from Biosimilars

More from Biosimilars & Generics